← Scroll for more →
Beam Therapeutics Inc. (BEAM)
Biological Products, (No Diagnostic Substances)
Latest Price
$27.23
TTM P/E
--
Normalized P/E
--
TTM Div Yield
--
Fwd Div Yield
--
Book Value
10.38
P/B Ratio
2.62
Institutional Ownership
100.0% held by institutions| Institution | Shares | Value | Ownership % | Change | Filing Date |
|---|---|---|---|---|---|
| FMR LLC | 12.61M | $432.0M | 12.21% | +156.8K | 2026-06-30 |
| Farallon Capital Management, L.L.C. | 10.24M | $351.0M | 9.91% | -- | 2026-06-30 |
| ARK Investment Management LLC | 10.23M | $351.0M | 9.91% | -1.90M | 2026-06-30 |
| BlackRock, Inc. | 9.00M | $308.0M | 8.71% | +510.0K | 2026-06-30 |
| State Street Corp | 5.83M | $199.0M | 5.64% | +127.9K | 2026-06-30 |
| Vanguard Portfolio Management LLC | 4.92M | $168.0M | 4.77% | +350.5K | 2026-06-30 |
| Vanguard Capital Management LLC | 4.60M | $157.0M | 4.45% | +222.1K | 2026-06-30 |
| ARCH Venture Management, LLC | 4.54M | $155.0M | 4.40% | -- | 2026-06-30 |
| Sumitomo Mitsui Trust Group, Inc. | 3.46M | $118.0M | 3.35% | -370.5K | 2026-06-30 |
| Price T Rowe Associates Inc | 3.42M | $117.0M | 3.31% | +702.0K | 2026-06-30 |